Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 100%High 0 · 0%

HAART + pegylated liposomal doxorubicin vs HAART + liposomal daunorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Moderate

HAART + pegylated liposomal doxorubicin vs HAART alone

Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 9 [0.61, 133.08]
1 study · 10 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in progression of Kaposi's sarcoma compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.07, 15.73]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ complete response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 2.08 [0.2, 21.5]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.5, 2.17]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.63 [0.27, 1.45]
1 study · 49 participants
Moderate